Agilent Technologies (A)
(Delayed Data from NYSE)
$137.32 USD
+2.34 (1.73%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $137.32 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$137.32 USD
+2.34 (1.73%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $137.32 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Zacks News
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG). The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce.
Top Stock Reports for Oracle, Progressive & MercadoLibre
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), The Progressive Corporation (PGR) and MercadoLibre, Inc. (MELI).
Agilent (A) Boosts DGG Segment With ProteoAnalyzer System
by Zacks Equity Research
Agilent (A) bolsters protein analysis capabilities with the ProteoAnalyzer system.
FTV vs. A: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FTV vs. A: Which Stock Is the Better Value Option?
Why Is Agilent (A) Up 12.8% Since Last Earnings Report?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent (A) Enhances BioTek Cytation C10 With New Technology
by Zacks Equity Research
Agilent (A) adds a water immersion and confocal spinning disk technology to BioTek Cytation C10, enhancing image quality and reducing harmful effects on live-cell samples.
The Zacks Analyst Blog Highlights Visa, Marriott International, Parker-Hannifin, FedEx and Agilent Technologies
by Zacks Equity Research
Visa, Marriott International, Parker-Hannifin, FedEx and Agilent Technologies are part of the Zacks top Analyst Blog.
Top Research Reports for Visa, Marriott International & Parker-Hannifin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Marriott International, Inc. (MAR) and Parker-Hannifin Corporation (PH).
Agilent (A) Q4 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Agilent's (A) fourth-quarter fiscal 2023 results are hurt by weakness in the LSAG segment and softness in the China market.
Agilent (A) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Agilent (A) give a sense of how its business performed in the quarter ended October 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
A November to Remember As The Rally Continues on a Goldilocks Market Scenario
by Mayur Thaker
soft landing is now the base case, but how likely is it?
What to Note Ahead of Agilent Technologies' (A) Q4 Earnings
by Zacks Equity Research
Agilent's (A) results for the fiscal fourth quarter are expected to reflect strength across the ACG amid weakness in the LSAG segment.
Agilent (A) Boosts DGG Offerings With PD-L1 IHC 22C3 Approval
by Zacks Equity Research
Agilent (A) receives FDA approval for its PD-L1 IHC 22C3 diagnostic tool, benefiting PD1/PDL1 cancer patients.
Agilent Technologies (A) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Agilent Technologies (A) stood at $113.60, denoting a +1.78% change from the preceding trading day.
Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agilent Technologies (A) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Agilent Technologies (A) reachead $109.39 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.
Agilent Technologies (A) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Agilent Technologies (A) stood at $102.86, denoting a -0.49% change from the preceding trading day.
Ametek (AME) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Ametek (AME) delivered earnings and revenue surprises of 3.80% and 1.55%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Agilent Technologies (A) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Agilent Technologies (A) stood at $104.31, denoting a +0.88% change from the preceding trading day.
Agilent (A) Bolsters NTD Research With SIDC Partnership
by Zacks Equity Research
Agilent (A) collaborates with Sarawak Infectious Disease Centre to provide the latter with its 6475 triple quadrupole LC/MS system, enabling rapid outbreak response for neglected tropical diseases.
Agilent (A) Boosts Genomic Profiling With New Collaboration
by Zacks Equity Research
Agilent (A) collaborates with the National Cancer Centre Singapore to accelerate Asian-prevalent cancer research over the next two years.
Agilent (A) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Agilent (A) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Agilent (A) stock based on the movements in the options market lately.
Agilent (A) Q3 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Agilent Technologies' (A) third-quarter fiscal 2023 results reflect weakness in the LSAG segment and China market.
Markets Remain Sold; H&R Block (HRB), Agilent (A) Beat
by Mark Vickery
The Dow slid -360 points in today's trading session, -1.02%, while the Nasdaq was down -157 points, -1.14%.
Agilent (A) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended July 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.